Macrophage Therapy For Acute Liver Injury (MAIL)

The aim of this trial is to test the safety and tolerability of macrophage cell therapy in acute liver injury following paracetamol overdose.

Macrophage Therapy For Acute Liver Injury (MAIL) Trial: A Phase 1 Randomised, Blinded, Dose-Escalation Study to Evaluate Safety, Tolerability, and Activity of Allogeneic Alternatively Activated Macrophages (AAM) in Patients with Paracetamol-induced Acute Liver Injury.

MAIL macrophages in acute liver injury logo

Chief Investigator: Professor James Dear 

Number and location of participating sites (by region/country): Edinburgh Royal Infirmary and Royal Victoria Infirmary, Newcastle

ISRCTN number: ISRCTN12637839

 

Funder:  Medical Research Council

Start and End date

Of grant award: 01 December 2022 - 30 November 2025

Of recruitment: 01 September 2023 - 31 May 2025

Current Status: Recruiting

 

Sponsor: University of Edinburgh and NHS Lothian -  https://www.accord.scot/

 

Chief Investigator:  Professor James Dear, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ

Trial Manager:  Edinburgh Clinical Trials Unit, Usher Building, The University of Edinburgh, 5-7 Little France Road, Edinburgh BioQuarter ‒ Gate 3, Edinburgh EH16 4UX Email: MAIL.Trial@ed.ac.uk

 

UK GDPR Privacy Statement: Contained within the patient information booklet

 

ECTU involvement: Trial Management / Statistics / Database

This article was published on